Prime Medicine (NASDAQ:PRME) Stock Price Down 5.6% – Here’s Why

Prime Medicine, Inc. (NASDAQ:PRMEGet Free Report)’s share price fell 5.6% during trading on Monday . The company traded as low as $4.15 and last traded at $4.18. 759,955 shares changed hands during trading, a decline of 77% from the average session volume of 3,331,140 shares. The stock had previously closed at $4.43.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on PRME. Wall Street Zen cut Prime Medicine from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Lifesci Capital raised shares of Prime Medicine to a “strong-buy” rating in a research note on Tuesday, December 23rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Prime Medicine in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Get Our Latest Stock Analysis on Prime Medicine

Prime Medicine Trading Down 5.6%

The stock has a market cap of $754.54 million, a price-to-earnings ratio of -2.90 and a beta of 2.71. The stock’s 50-day simple moving average is $3.83.

Prime Medicine (NASDAQ:PRMEGet Free Report) last posted its quarterly earnings data on Friday, November 7th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). The firm had revenue of $1.23 million during the quarter. Prime Medicine had a negative return on equity of 163.51% and a negative net margin of 3,301.64%.

About Prime Medicine

(Get Free Report)

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof.

Featured Stories

Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.